Lecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer’s disease (AD) who were α-synuclein positive, a subgroup associated with higher amyloid burden and faster clinical decline TOKYO and CAMBRIDGE, Mass., Nov. 19,…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks

